Cytidine 51-diphosphocholine or citicoline is an endogenous compound that acts in the biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown positive effects in Parkinson’s disease and Alzheimer’s disease, as well as in amblyopia. Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures. Neuroprotection has been proposed as a valid therapeutic option for those patients progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of the disease. The aim of this review is to critically summarize the current evidence about the effect of citicoline in glaucoma.

Roberti, G., Tanga, L., Michelessi, M., Quaranta, L., Parisi, V., Manni, G., et al. (2015). Cytidine 51-diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 16(12), 28401-28417 [10.3390/ijms161226099].

Cytidine 51-diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives

Manni G.;
2015-01-01

Abstract

Cytidine 51-diphosphocholine or citicoline is an endogenous compound that acts in the biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown positive effects in Parkinson’s disease and Alzheimer’s disease, as well as in amblyopia. Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures. Neuroprotection has been proposed as a valid therapeutic option for those patients progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of the disease. The aim of this review is to critically summarize the current evidence about the effect of citicoline in glaucoma.
2015
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/30 - MALATTIE APPARATO VISIVO
English
Citicoline
Glaucoma
Neuroprotection
Retinal ganglion cells
Roberti, G., Tanga, L., Michelessi, M., Quaranta, L., Parisi, V., Manni, G., et al. (2015). Cytidine 51-diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 16(12), 28401-28417 [10.3390/ijms161226099].
Roberti, G; Tanga, L; Michelessi, M; Quaranta, L; Parisi, V; Manni, G; Oddone, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/314773
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 36
  • ???jsp.display-item.citation.isi??? ND
social impact